Spur Therapeutics

Executive Summary

Spur Therapeutics is a clinical-stage biotechnology company based in London, UK, founded in 2021, that is developing next-generation gene therapies aimed at altering the course of debilitating chronic diseases with a single dose. The company leverages a proprietary platform to optimize gene expression, packaging, and delivery, targeting a spectrum from rare to more prevalent conditions. With a Phase 1/2 stage, Spur focuses on creating durable treatments that address underlying disease mechanisms. Its approach has the potential to transform patient outcomes by reducing the burden of lifelong therapies. The company's early-stage pipeline and platform versatility position it for growth, though it faces typical development risks and capital requirements common in gene therapy.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 interim data readout for lead gene therapy candidate50% success
• Q4 2026Regulatory update or IND filing for next pipeline program60% success
• Q2 2027Partnership or collaboration announcement for platform technology40% success